Consistent with Kardigan’s mission to develop targeted treatments for patients with cardiovascular diseases, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible.
At this time, Kardigan provides access to its investigational drug products, which have not been approved by FDA or other regulatory authorities, only through participation in clinical trials. Access to Kardigan’s investigational drug products for those not participating in Kardigan clinical trials is not currently possible. For more information about this policy, please contact [email protected]. More information about Kardigan’s clinical trials is available at www.clinicaltrials.gov.
Kardigan reserves the right to review and update this expanded access policy at any time.